November 4, 2025
November 4, 2025 — Leads & Copy — Veracyte, Inc. (Nasdaq: VCYT) reported strong third-quarter financial results, with testing revenue up 17% to $127.8 million and adjusted EBITDA reaching $39.7 million. The company has raised its full-year revenue guidance to $506 million-$510 million. Key business highlights included presentations at ASTRO 2025 and the American Thyroid Association Annual Meeting, as well as the launch of the Afirma v2 transcriptome.
Total revenue for the third quarter of 2025 reached $131.9 million, a 14% increase from $115.9 million in the third quarter of 2024. Testing revenue grew 17% to $127.8 million, driven by Decipher Prostate and Afirma tests. GAAP net income was $19.1 million, and adjusted EBITDA was $39.7 million, representing 30% of revenue. The company ended the quarter with $366.4 million in cash and short-term investments.
Veracyte has raised its full-year testing revenue guidance to $484 million to $487 million, reflecting a 16% year-over-year increase. Total revenue guidance is now $506 million to $510 million, a 14% rise. The company also anticipates an adjusted EBITDA margin of over 25% for 2025.
Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. The webcast can be accessed at https://edge.media-server.com/mmc/p/kcexjtb4, and a replay will be available on the company’s website.
For more information, visit www.veracyte.com.
Source: Veracyte, Inc.
